Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis
Open accessThe DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.
Abstract
BACKGROUND & AIMS: Interactions between C-C chemokine receptor types 2 (CCR2) and 5 (CCR5) and their ligands, including CCL2 and CCL5, mediate fibrogenesis by promoting monocyte/macrophage recruitment and tissue infiltration, as well as hepatic stellate cell activation. Cenicriviroc (CVC) is an oral, dual CCR2/CCR5 antagonist with nanomolar potency against both receptors. CVC's anti-inflammatory and antifibrotic effects were evaluated in a range of preclinical models of inflammation and fibrosis. METHODS: Monocyte/macrophage recruitment was assessed in vivo in a mouse model of thioglycollate-induced peritonitis. CCL2-induced chemotaxis was evaluated ex vivo on mouse monocytes. CVC's antifibrotic effects were evaluated in a thioacetamide-induced rat model of liver fibrosis and mouse models of diet-induced non-alcoholic steatohepatitis (NASH) and renal fibrosis. Study assessments included body and liver/kidney weight, liver function test, liver/kidney morphology and collagen deposition, fibrogenic gene and protein expression, and pharmacokinetic analyses. RESULTS: CVC significantly reduced monocyte/macrophage recruitment in vivo at doses ≥20 mg/kg/day (p < 0.05). At these doses, CVC showed antifibrotic effects, with significant reductions in collagen deposition (p < 0.05), and collagen type 1 protein and mRNA expression across the three animal models of fibrosis. In the NASH model, CVC significantly reduced the non-alcoholic fatty liver disease activity score (p < 0.05 vs. controls). CVC treatment had no notable effect on body or liver/kidney weight. CONCLUSIONS: CVC displayed potent anti-inflammatory and antifibrotic activity in a range of animal fibrosis models, supporting human testing for fibrotic diseases. Further experimental studies are needed to clarify the underlying mechanisms of CVC's antifibrotic effects. A Phase 2b study in adults with NASH and liver fibrosis is fully enrolled (CENTAUR Study 652-2-203; NCT02217475).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig 1 CVC Effect on Monocyte/Macrophage Migration. (A) Monocyte/macrophage recruitment reduced in TG-induced mouse model of peritonitis after pre-treatment with CVC (PO BID or QD dosing); (B) cenicriviroc (1 μM) inhibits CCL2-mediated chemotaxis of activated murine macrophages (F4/80+/CD11b+) ex vivo. *p < 0.05 vs. TG + vehicle control; **p < 0.01 vs. TG + vehicle control; ***p < 0.001 vs. TG + vehicle control; † p < 0.001 vs. TG + DEX; ‡ p = 0.018 vs. vehicle control. aVehicle control: 0.5% [w/v] methylcellulose + 1% Tween®-80 (pH ~1.3). BID, twice daily; CCL2, C-C chemokine ligand 2; CVC, cenicriviroc; CVC5, CVC 5 mg/kg/day; CVC20, CVC 20 mg/kg/day; CVC100, CVC 100 mg/kg/day; DEX, dexamethasone; PO, oral gavage; QD, once daily; SEM, standard error of the mean; TG, thioglycollate.](https://figures.cochat.ai/paper-figures/dfdd355eafec4c6e9c04f1a46b1d736c/antifibrotic-effects-of-the-dual-ccr2-ccr5-antagonist-cenicriviroc-in-animal-figure-1.jpg)
![Fig 2 Reduction of Plasma ALT Levels in NASH Model. *p < 0.05 vs. vehicle control. aVehicle control: 0.5% [w/v] methylcellulose + 1% Tween®-80 (pH ~1.3). ALT, alanine aminotransferase; BID, twice daily; CVC, cenicriviroc; CVC20, CVC 20 mg/kg/day; CVC100, CVC 100 mg/kg/day; NASH, non-alcoholic steatohepatitis; SD, standard deviation.](https://figures.cochat.ai/paper-figures/1a6e539bef254c4eae8e1034fb2ebd96/antifibrotic-effects-of-the-dual-ccr2-ccr5-antagonist-cenicriviroc-in-animal-figure-2.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“These preclinical studies demonstrated a significant reduction in collagen deposition (148).”
From Targeting macrophages in liver fibrosis (2026) · cites this paper as [148]
In the citing paper
“Pharmacological inhibition of CCL2 by mNOX-E36 (121) or the use of cenicriviroc, a CCR2/CCR5 antagonist, gave promising anti-inflammatory and antifibrogenic results in mouse models (122).”
From Immunoregulation of Liver Fibrosis: New Opportunities for Antifibrotic Therapy (2024) · doi:10.1146/annurev-pharmtox-020524-012013 · cites this paper as [122]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791 · cited 1×
“The NAS, a histological tool developed to assess disease severity in humans, was assessed in a blinded fashion and calculated according to Kleiner’s criteria on H&E-stained sections [38].”
MethodChronic kidney disease: global dimension and perspectives
Jha, V., Garcia-Garcia, G., Iseki, K., Li, Z., Naicker, S., Plattner, B., Saran, R., Wang, A. Y.-M., & Yang, C.-W. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60687-x · Cited by 4,383 · cited 1×
“Likewise, renal fibrosis is a common manifestation of chronic kidney disease [3], associated with elevated risks of morbidity and mortality [4].”
BackgroundPioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327 · cited 1×
“Pioglitazone, obeticholic acid and elafibranor have shown amelioration of insulin resistance and/ or antifibrotic activity in animal models [53–55] and have undergone Phase 2 clinical evaluation [50,51,56] (NCT01694849).”
BackgroundNeuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237 · cited 1×
“Pioglitazone, obeticholic acid and elafibranor have shown amelioration of insulin resistance and/ or antifibrotic activity in animal models [53–55] and have undergone Phase 2 clinical evaluation [50,51,56] (NCT01694849).”
BackgroundNonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities
Sanyal, A. J., Campbell–Sargent, C., Mirshahi, F., Rizzo, W. B., Contos, M. J., Sterling, R. K., Luketic, V. A., Shiffman, M. L., & Clore, J. N. (2001) · Gastroenterology · doi:10.1053/gast.2001.23256 · Cited by 2,078
Macrophage heterogeneity in liver injury and fibrosis
Tacke, F., & Zimmermann, H. W. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.12.025 · Cited by 1,061 · cited 1×
“transforming growth factor-beta [TGF-beta]), produced by activated macrophages, promote transdifferentiation of HSCs into myofibroblasts, which are the primary source of scarforming matrix proteins, including fibrillary collagen types 1 and 3, and the contractile protein alpha-smooth muscle actin (alpha-SMA) [1,6–8].”
BackgroundRatziu, V., Harrison, S. A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.038 · Cited by 1,035
Pathobiology of liver fibrosis: a translational success story
Lee, Y. A., Wallace, M. C., & Friedman, S. L. (2015) · Gut · doi:10.1136/gutjnl-2014-306842 · Cited by 894 · cited 2×
“Fibrosis results from a sustained inflammatory response to chronic organ injury and is characterized by the deposition of extracellular matrix proteins, including collagen types 1 and 3 [1].”
BackgroundSelf-citationRoles for chemokines in liver disease
Marra, F., & Tacke, F. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.06.043 · Cited by 829 · cited 1×
“CCR2 and CCR5 have become attractive targets for antifibrotic therapy, as interactions with their ligands, including CCL2 and CCL5, mediate recruitment of inflammatory cells to the site of liver injury, and contribute to fibrosis [9–15,40].”
BackgroundPradere, J.-P., Kluwe, J., De Minicis, S., Jiao, J.-J., Gwak, G.-Y., Dapito, D. H., Jang, M.-K., Guenther, N. D., Mederacke, I., Friedman, R., et al. (2013) · Hepatology · doi:10.1002/hep.26429 · Cited by 613 · cited 1×
“transforming growth factor-beta [TGF-beta]), produced by activated macrophages, promote transdifferentiation of HSCs into myofibroblasts, which are the primary source of scarforming matrix proteins, including fibrillary collagen types 1 and 3, and the contractile protein alpha-smooth muscle actin (alpha-SMA) [1,6–8].”
Background
Research works printed but not linked: 3
- Jalbert E, Byron MM, Shikuma C, Jenkins H, Lefebvre E, Barbour JD. Cenicriviroc achieves high CCR5 receptor occupancy at low nanomolar concentrations. Presented at: 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014); 2014 Mar 3; Boston, MA, USA. 530.
- MM Byron, 2015, Dual CCR2/CCR5 antagonism by cenicriviroc efficiently inhibits both MCP-1 and RANTES induced chemokine receptor internalization in murine pro-inflammatory monocytes, J Immunol, 194, 187, 10.4049/jimmunol.194.Supp.187.8 · DOI
- M Thompson, 2014, Improvements in APRI and FIB-4 fibrosis scores correlate with decreases in sCD14 in HIV-1 infected adults receiving cenicriviroc over 48 weeks, Hepatology, 60, 424A
Cited by
Items 301–326 of 326
Şentürk, M. (2022) · Biochemistry · doi:10.5772/intechopen.100950 · Cited by 1
Angeborene und erworbene Immunität im Kontext der nichtalkoholischen Fettlebererkrankung
Heinrich, B. (2023) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1993-3519
Eslami, M., Jalilian, F. A., Najafi, R., Mahdavinezhad, A., & Amini, R. (2023) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2023/5993866
The Roles of T Lymphocyte Subsets in the Pathogenesis of NAFLD
许, 琳. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.151105
Hummel, K., Stefansson, L., Gilbert, K. F., Amontree, M., Ma, J., Pak, D. T. S., & Conant, K. E. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.12.675856
Immune landscape and molecular regulators in renal interstitial fibrosis
He, M. X., Kasimumali, A., Guo, S., Meng, H., & Rong, S. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115702 · Cited by 1
Thakurdesai, P. A., & Pujari, R. (2025) · International Journal of Pharmacy and Pharmaceutical Sciences · doi:10.22159/ijpps.2025v17i12.56661
Lowe, P., Morel, C., Ambade, A., Iracheta‐Vellve, A., Kwiatkowski, E. R., Satishchandran, A., Fűri, I., Cho, Y., Gyöngyösi, B., Catalano, D., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13076501
Self-citationBukkuri, A., McLaughlin, J., Duncan, A. W., & Stallaert, W. (2026) · Evolution Medicine and Public Health · doi:10.1093/emph/eoag002
“To do this, we will use a recently developed mouse model that mimics pathologic sequelae of MASH-induced HCC in humans [56 ---60 ] and has been used for testing novel antifibrotic [61] and anti-MASH drugs [62 ].”
Cutrone, A. M., Yeh, H., Uygun, K., & Usta, O. B. (2026) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-081325-053420
Tsuji, K. (2026) · Diagnostics · doi:10.3390/diagnostics16040549 · Cited by 1
Homéostasie des céramides et hépatopathies métaboliques
Régnier, M. (2018) · theses.fr (ABES) · doi:10.70675/2fb92711z373cz4b27z8082z7aa3f8930e63 · Cited by 1
Influence du sexe dans la susceptibilité aux hépatopathies métaboliques
Smati, S. (2019) · theses.fr (ABES) · doi:10.70675/01997f55za990z41e6z96baz8221de2a6281
Rôle de FAT10 dans la sénescence des hépatocytes et le développement de la NASH
Bernard, L. (2023) · theses.fr (ABES) · doi:10.70675/793b0b93z9794z42d4zb8dfz5f3d68268a9b
Review of Liver Fibrosis and Inflammation
Zeng, Q. (2026) · BIO Web of Conferences · doi:10.1051/bioconf/202623204008
Sun, X., Jiang, H.-L., Ma, Y.-T., Xiong, T.-Q., Leng, X.-Y., Zhao, Y.-F., Shen, X., Zhang, C., & Tang, Y.-J. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08219-6 · Cited by 1
“Cenicriviroc, a dual CCR2/CCR5 antagonist [56], exerted antifibrotic effects by significantly reducing the recruitment of mononuclear phagocytes.”
Slc44a2 Deficiency Unveils an IFN‐I–Dependent Feedback Control of pDC Egress
Chen, R., Wu, T., Shi, Z., Verma, R. K., Sheng, L., Tao, L., Yang, M., Wang, Y., Zhang, C., Fan, H., et al. (2026) · Advanced Science · doi:10.1002/advs.76325
CCR2/CCR5 Signaling Defines a Pathogenic Interstitial Macrophage Subset That Drives Severe Asthma
Wang, H., Fung, N. H., Aloe, C. A., Kermani, N. Z., Adcock, I. M., Selemidis, S., Vlahos, R., McQualter, J. L., & Bozinovski, S. (2026) · Clinical and Translational Allergy · doi:10.1002/clt2.70201
Context-Dependent Roles of Liver Macrophages in MASH
Horn, P., & Tacke, F. (2026) · Seminars in Liver Disease · doi:10.1055/a-2954-5433
A microglial SPP1-ITGB1 feedback loop sustains thalamic hyperexcitability and post-stroke pain
Dai, R., Wu, W., 周翔宇, Zhou, Y., Gao, X., & Luo, M. (2026) · Neuron · doi:10.1016/j.neuron.2026.08.028
BindingDB (2022) · UC San Diego · doi:10.7270/q2m04981
BindingDB Entry 50018374: Advances of CCR5 antagonists: From small molecules to macromolecules.
BindingDB (2024) · UC San Diego · doi:10.7270/q2gx4gsw
BindingDB (2021) · UC San Diego · doi:10.7270/q2dj5jxg
Lu, W., Xu, J., Wang, K., Chen, Y., Cherubini, A., Valenti, L. V. C., Zheng, S., & Liu, Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1954491
Metadata
- Authors
- Lefebvre, E., Moyle, G., Reshef, R., Richman, L. P., Thompson, M., Hong, F., Chou, H.-L., Hashiguchi, T., Plato, C., Poulin, D., Richards, T., Yoneyama, H., Jenkins, H., Wolfgang, G., & Friedman, S. L.
- Affiliations
- Chelsea and Westminster Hospital (GB)
- Columbia University Irving Medical Center (US)
- University of Pennsylvania (US)
- AIDS Research Consortium of Atlanta (US)
- Icahn School of Medicine at Mount Sinai (US)
- Stelic (Japan) (JP)
- Charles River Laboratories (Canada) (CA)
- Corresponding author
- Friedman, Scott L.
- ORCID
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-06-27
- Volume
- 11
- Issue
- 6
- Pages
- e0158156
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4922569
- OpenAlex
- W2467384826
- Cited by
- 323
- References
- 51
- Citations by year
- 2026: 17 · 2025: 20 · 2024: 23 · 2023: 28 · 2022: 33 · 2021: 40 · 2020: 46 · 2019: 30 · 2018: 50 · 2017: 28 · 2016: 8
- FWCI
- 27.92
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Columbia Academic Commons (Columbia University)
- Funders
- National Institute of General Medical Sciences (T32GM007170)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Oncology › Chemokine receptors and signaling
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Keywords
- cenicriviroc, antifibrotic effect, liver fibrosis, renal fibrosis, nonalcoholic steatohepatitis, monocyte/macrophage recruitment, MCP-1, RANTES, hepatic stellate cell activation, collagen deposition, chemokine signaling, thioacetamide-induced liver fibrosis, diet-induced NASH
- MeSH terms
- Animals, Chemotaxis, Fibrosis, Imidazoles, Kidney Diseases, Macrophages, Male, Mice, Inbred C57BL, Monocytes, Sulfoxides, Rats, Sprague-Dawley, Mice, Rats, Receptors, CCR2, CCR5 Receptor Antagonists, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.